Peroxisome Proliferator-Activated Receptors and their Ligands in Cancer Drug- Resistance: Opportunity or Challenge

Author(s): Bahman Yousefi, Nosratollah Zarghami, Nasser Samadi, Maryam Majidinia

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 16 , Issue 12 , 2016

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Development of resistance in cancer cells results in a high failure rate in cancer chemotherapy in the clinic. Therefore, investigating the mechanisms by which cancer cells acquire the capability to avoid cell death upon exposure to antineoplastic agents is of great significance in cancer research. In this review article, we will provide an overview of the mechanisms and molecular machinery of drug resistance in cancer cells which include but may not be limited to altered membrane transport and drug metabolizing enzymes, genetic response, enhanced DNA repair and alternation in the target molecules. A special focus will be on describing the strategies and the rationale for exploitation of peroxisome proliferator-activated receptors for overcoming the observed resistance in cancer cells.

Keywords: Cancer, chemotherapy, drug resistance, PPARs, P-glycoprotein, thiazolidinedione.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [1541 - 1548]
Pages: 8
DOI: 10.2174/1871520616666160204112941
Price: $65

Article Metrics

PDF: 45
PRC: 1